Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs MMF in Pemphigus Vulgaris
NCT02383589Phase 3Completed
- Sponsor
- Roche
- Start
- May 2015
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of rituximab in pemphigus vulgaris (PV), sponsored by Roche. Started May 2015; status: completed.
02
Drugs
rituximab
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on NCT02383589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02383589.